PLX-4720

For research use only.

Catalog No.S1152

129 publications

PLX-4720 Chemical Structure

CAS No. 918505-84-7

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 477 In stock
USD 670 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PLX-4720 has been cited by 129 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 NFfOdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTkSlZiUUN3ME2wMlA4PDV5IN88US=> MWfTRW5ITVJ?
EoL-1-cell NFnlZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H1SGlEPTB;MD6xOFE3PiEQvF2= M{XB[nNCVkeHUh?=
C32 NHX2e|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMUWxN|Eh|ryP MmHjV2FPT0WU
M14 NY\XbpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\Eeo9KSzVyPUCuNlE4PTdizszN MWnTRW5ITVJ?
CP50-MEL-B MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX3VpRHUUN3ME2wMlI6Pzh2IN88US=> MVXTRW5ITVJ?
A101D NYnMVo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvqfm1xUUN3ME2wMlMzPTh7IN88US=> MYnTRW5ITVJ?
G-361 NIrFfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\KV4hzUUN3ME2wMlM1PjN5IN88US=> MmH5V2FPT0WU
HT-144 NUHSWHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVTWM2OD1yLkO2N|I6KM7:TR?= MmnQV2FPT0WU
ACN M1vPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO4XXdKSzVyPUCuN|g1PzdizszN MUfTRW5ITVJ?
COLO-829 M3fWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JXmlEPTB;MD6zPFk3QCEQvF2= NXztR|FnW0GQR1XS
MEL-HO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zTdGlEPTB;MD60NVE4QSEQvF2= MoTIV2FPT0WU
SH-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nuR2lEPTB;MD60NVQzOiEQvF2= M2nYSXNCVkeHUh?=
SK-MEL-3 NWTkcFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPzXnRKSzVyPUCuOVE2PjhizszN M4XwW3NCVkeHUh?=
A375 M3z3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOwTWM2OD1yLk[3N|U6KM7:TR?= NVK1RYZ7W0GQR1XS
MMAC-SF NI\YPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrHd5ZKSzVyPUCuOlg3OTRizszN NWnlfGlDW0GQR1XS
BHT-101 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwN{C3NFIh|ryP MXPTRW5ITVJ?
K5 NWrVS|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu2TWM2OD1yLke2NVQ5KM7:TR?= MUTTRW5ITVJ?
BV-173 M4DSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED1TINKSzVyPUCuO|k3PDRizszN M1TzVXNCVkeHUh?=
RVH-421 NUPxc2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwOE[3PVYh|ryP NHjHdVhUSU6JRWK=
HCC2218 NGDhW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjjcmpKSzVyPUCuPFc5PDRizszN NFnESplUSU6JRWK=
WM-115 M3O4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWxO2ZKSzVyPUCuPFg3QTJizszN MULTRW5ITVJ?
SK-MEL-28 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXVRlFXUUN3ME2xMlA1PTZ7IN88US=> Mn;iV2FPT0WU
COLO-679 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\1XmZKSzVyPUGuNVA1PjRizszN MVfTRW5ITVJ?
MZ7-mel M{\5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjFc4hKSzVyPUGuNVQ6PjNizszN MmnOV2FPT0WU
SK-MEL-30 NIj2NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTLTWM2OD1zLkOzN|g3KM7:TR?= M2jyO3NCVkeHUh?=
NCI-H209 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwNkC4OkDPxE1? Mke5V2FPT0WU
HTC-C3 NGfKXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwNk[yPVQh|ryP MnfBV2FPT0WU
KARPAS-45 NVzW[ZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJwMES5O|gh|ryP NV:5T3lEW0GQR1XS
NCI-SNU-5 NHX3NphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP2TWM2OD1{LkGxPVY6KM7:TR?= MX;TRW5ITVJ?
KP-4 NXzxe5pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvXUXFKSzVyPUKuN|A4QDdizszN MmjnV2FPT0WU
PA-1 M3fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZUmlEPTB;Mj63NlY4OyEQvF2= MXLTRW5ITVJ?
HuO-3N1 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHXTWM2OD1{Lki3PVQ3KM7:TR?= NH[0UWpUSU6JRWK=
NCI-H358 NXi2e5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwOUKyN|Ih|ryP MkjyV2FPT0WU
CTB-1 NVLrVWhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPTbZRKSzVyPUOuOFAyPzZizszN NIXvSYdUSU6JRWK=
697 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXJPI9VUUN3ME2zMlU2OjZ4IN88US=> NGfwbWFUSU6JRWK=
CP66-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwMUW5Nlch|ryP M2jTSHNCVkeHUh?=
NB13 M2LOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHpTWM2OD12LkS5NVc6KM7:TR?= MWrTRW5ITVJ?
DBTRG-05MG NEW1V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPaTWM2OD12LkWzN|I2KM7:TR?= M4Pac3NCVkeHUh?=
A2058 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPMTWM2OD12LkeyNVY1KM7:TR?= MmLWV2FPT0WU
KG-1 NVvuT5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HVOGlEPTB;ND63N|kxQCEQvF2= NH\ISm5USU6JRWK=
8305C NED6SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrhTWM2OD13LkG4O|Mh|ryP M370RnNCVkeHUh?=
RPMI-7951 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D0OmlEPTB;NT64NFI5OyEQvF2= M4DUZnNCVkeHUh?=
CHL-1 M2HnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHEPWhKSzVyPUWuPVc3ODNizszN MWLTRW5ITVJ?
TI-73 M4\xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jTV2lEPTB;Nj6wNFkxOiEQvF2= NIHucFhUSU6JRWK=
HT-1080 NIC0e2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEd2lEPTB;Nj6xNFk1PiEQvF2= NI\6ZoJUSU6JRWK=
ES5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLYWFR5UUN3ME22MlE1QTJ2IN88US=> MYjTRW5ITVJ?
8-MG-BA M1HRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLCZ3N3UUN3ME22MlE5OTJ7IN88US=> MmLqV2FPT0WU
NB7 NFTBOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;l[HlKSzVyPU[uNlE{PzNizszN M3HrZXNCVkeHUh?=
H4 NVflZWl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTZwMkK0PVMh|ryP MmC4V2FPT0WU
CAL-72 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W1RWlEPTB;Nj60OVQzOyEQvF2= MojQV2FPT0WU
HCC1806 NX\lV|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTZwOEG5N|Eh|ryP NGjxNphUSU6JRWK=
BCPAP NYnKSVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\hVpdKSzVyPUeuNlE4PjRizszN NV;TWHpQW0GQR1XS
LB2241-RCC NGewVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTdwM{[5NFch|ryP M{X3T3NCVkeHUh?=
COLO-741 NE\WTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRThwMEG2O|kh|ryP M36zNnNCVkeHUh?=
HSC-3 NHnQPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3FTWM2OD16LkC3NFY5KM7:TR?= MYjTRW5ITVJ?
SW982 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Q[olKSzVyPUiuOFE2OTZizszN MljxV2FPT0WU
GCT NE\FRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj1dGJKSzVyPUiuO|U{OTRizszN NXHjSZloW0GQR1XS
KY821 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDybXZKSzVyPUmuNFUyPzhizszN M4K0W3NCVkeHUh?=
JVM-3 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTlwNU[5PVkh|ryP NVyzRWlGW0GQR1XS
RS4-11 NGH3SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnIdVlKSzVyPUmuOlA1QCEQvF2= NUTuNmR1W0GQR1XS
VA-ES-BJ MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFyLkCxOFkh|ryP NYL3V25wW0GQR1XS
A431 MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorlTWM2OD1zMD60NlEzKM7:TR?= MWDTRW5ITVJ?
LXF-289 M4HqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfvOG1uUUN3ME2xNE41PThizszN M{niNnNCVkeHUh?=
SK-MEL-24 NWmwdYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nhfWlEPTB;MUCuPFI4PCEQvF2= M2K1WnNCVkeHUh?=
NOS-1 NWHXbWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPL[3JoUUN3ME2xNE45PDd{IN88US=> MUnTRW5ITVJ?
KNS-62 NHfl[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e5VmlEPTB;MUGuNlQxPCEQvF2= M{mxbnNCVkeHUh?=
SK-HEP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknJTWM2OD1zMT6zOVI4KM7:TR?= NHW2TJNUSU6JRWK=
A3-KAW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFzLkexO|gh|ryP M4r0O3NCVkeHUh?=
SK-LU-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjlRmJzUUN3ME2xNk4zPjV3IN88US=> NV\UXHdkW0GQR1XS
TYK-nu Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzycXNKSzVyPUGyMlM6OzJizszN M1\lNXNCVkeHUh?=
NMC-G1 NGTMXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{Lk[wOlIh|ryP MUPTRW5ITVJ?
BB65-RCC NIW5c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF{LkexOlkh|ryP MXfTRW5ITVJ?
QIMR-WIL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT4WmxKSzVyPUGyMlg5OzNizszN MkH5V2FPT0WU
D-566MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj2TWM2OD1zMz65OVc3KM7:TR?= MkDsV2FPT0WU
KYSE-140 M1fEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3KTWM2OD1zND6wO|U{KM7:TR?= MXHTRW5ITVJ?
SCC-4 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnHTWM2OD1zND6zN|U6KM7:TR?= MUXTRW5ITVJ?
U251 NGDkWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsfGlEPTB;MUSuPFQ6OiEQvF2= MXnTRW5ITVJ?
D-542MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvyVGlKSzVyPUG0MlkzOjJizszN MX7TRW5ITVJ?
LAMA-84 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPM[pVyUUN3ME2xOE46QTN{IN88US=> NH;TUZhUSU6JRWK=
NCI-H720 NXX1foNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LqNmlEPTB;MUWuNlY5PCEQvF2= NVPndHVyW0GQR1XS
DEL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXzOpBKSzVyPUG1MlQzQTNizszN NGHxRnlUSU6JRWK=
SBC-1 NInjbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPYSm1WUUN3ME2xOU41OzB3IN88US=> NFHZ[YVUSU6JRWK=
ECC10 NFrGdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XWZmlEPTB;MUWuOFQ2QCEQvF2= Mm\tV2FPT0WU
Daoy NXHWO3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrLOoJyUUN3ME2xOU44PjF4IN88US=> Mn7EV2FPT0WU
SCH MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:4UFRbUUN3ME2xOU44QDN3IN88US=> Ml73V2FPT0WU
MZ2-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3OWlEPTB;MU[uNFY1PiEQvF2= NFvPPGhUSU6JRWK=
CAL-12T NFq3R4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDvTWM2OD1zNj60PFYzKM7:TR?= MnPMV2FPT0WU
KE-37 M3zLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF4LkixNFch|ryP NHjqSY5USU6JRWK=
LS-411N NUPwNlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF5LkGxPEDPxE1? M2HydHNCVkeHUh?=
NCI-H2228 MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHrTWM2OD1zNz6zNFcyKM7:TR?= NGLMUXBUSU6JRWK=
SK-MEL-2 NWDTNlR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG0TWM2OD1zNz60PVY2KM7:TR?= MkHOV2FPT0WU
HN NFLSfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS3W3BKSzVyPUG3MlczPDhizszN NUW2N3VsW0GQR1XS
NCI-H1648 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HxSmlEPTB;MUeuPFE5KM7:TR?= MlfnV2FPT0WU
IA-LM NVjoTFBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnEb4JpUUN3ME2xPE4{OTd{IN88US=> M2DMbXNCVkeHUh?=
EW-13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nsfmlEPTB;MUiuOVcxQCEQvF2= M4HXXnNCVkeHUh?=
YKG-1 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvVNFZFUUN3ME2xPU42PzFzIN88US=> MWHTRW5ITVJ?
KNS-81-FD NUnkdmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPWe|FkUUN3ME2xPU42QDV6IN88US=> M3nkdXNCVkeHUh?=
23132-87 NYDxR2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELR[mlKSzVyPUG5Mlc3PDJizszN M4frbnNCVkeHUh?=
NUGC-3 NXjrfm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTtTWM2OD1zOT65PFg4KM7:TR?= MVjTRW5ITVJ?
5637 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJyLkC0O|gh|ryP MXTTRW5ITVJ?
NCI-H1755 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD1{MD60O|Y1KM7:TR?= MUDTRW5ITVJ?
RH-18 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjsN5VKSzVyPUKwMlU4PDhizszN NYH4SGJ4W0GQR1XS
RXF393 NIjybXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfubGdKSzVyPUKwMlY4PTZizszN NWT5OGRvW0GQR1XS
LU-134-A NWTWXZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2NmlEPTB;MkCuO|A2PiEQvF2= MYjTRW5ITVJ?
TE-12 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJyLkeyNFEh|ryP M3n1V3NCVkeHUh?=
MOLT-4 NFv5fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;uTWM2OD1{MT6xPVE2KM7:TR?= MorxV2FPT0WU
IGR-1 M1P5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSye|JkUUN3ME2yNU4{Pzl4IN88US=> MVTTRW5ITVJ?
HOP-92 NFfRUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:zdm1KSzVyPUKxMlQ6QDdizszN NHrnV2VUSU6JRWK=
SK-MES-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4TWM2OD1{MT63N|gyKM7:TR?= M1PUTHNCVkeHUh?=
LU-65 NWrFUXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHQfZRKSzVyPUKxMlg3OjRizszN NE\ScoZUSU6JRWK=
MS-1 NUHQOGRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ{LkGyNFMh|ryP NE\McZdUSU6JRWK=
LoVo MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPo[4JNUUN3ME2yNk4zPDRizszN NXi5Z4Q4W0GQR1XS
A704 M4LPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXGfo5KSzVyPUKyMlUyPTVizszN NHOxR2JUSU6JRWK=
HT-1376 NELIRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ{Lk[wOVkh|ryP M{[0[nNCVkeHUh?=
IST-MEL1 M{\xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W5SmlEPTB;MkKuOlc2OSEQvF2= M1jFSXNCVkeHUh?=
Ramos-2G6-4C10 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT5TWM2OD1{Mj63N|Y3KM7:TR?= M3HuTnNCVkeHUh?=
T47D Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ{Lke5O|kh|ryP NFnwPWNUSU6JRWK=
HT-1197 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfyTWM2OD1{Mz6wPFE4KM7:TR?= NX;xR3NMW0GQR1XS
LB2518-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPaTWM2OD1{Mz62OFEzKM7:TR?= NGPEZ|VUSU6JRWK=
J-RT3-T3-5 NHPqRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyxRoVKSzVyPUK0Mlc2QTVizszN MVjTRW5ITVJ?
SK-NEP-1 NVziepRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPOTWM2OD1{ND64O|Q1KM7:TR?= Mnm2V2FPT0WU
NCI-H526 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;rTWM2OD1{NT6wNFI{KM7:TR?= M2jzVXNCVkeHUh?=
IST-SL1 M37Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom5TWM2OD1{NT6yO|UyKM7:TR?= Mn3SV2FPT0WU
HH MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j5O2lEPTB;MkWuN|E6OiEQvF2= NESyfYFUSU6JRWK=
NCI-H82 NGjuWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTDbpdKSzVyPUK1Mlk{QCEQvF2= MVPTRW5ITVJ?
SNU-449 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ5LkKwNVgh|ryP NH3Ke4xUSU6JRWK=
COR-L23 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ5LkK4NVMh|ryP MknmV2FPT0WU
LOXIMVI Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv4OY9bUUN3ME2yO{4{PjhizszN MXLTRW5ITVJ?
GR-ST MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD4TWM2OD1{Nz62O|A3KM7:TR?= MljRV2FPT0WU
NCI-SNU-1 M2jqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTYbodXUUN3ME2yO{46PDRizszN NXe2W2R3W0GQR1XS
ALL-PO NVj4cVVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVepB5UUN3ME2yPE4yPjB2IN88US=> MmS4V2FPT0WU
ML-2 NXLObYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHoTWM2OD1{OD6yPFE1KM7:TR?= NG\UNIVUSU6JRWK=
HOP-62 M{XzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnX[ohKSzVyPUK4MlcyOyEQvF2= NUTxRo1ZW0GQR1XS
EGI-1 NXWwVolsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\xTpd{UUN3ME2yPE45QDR3IN88US=> MUHTRW5ITVJ?
TCCSUP MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHwTWM2OD1{OD65NlczKM7:TR?= MlX5V2FPT0WU
LB996-RCC M3O5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CyOGlEPTB;MkmuOVY5OiEQvF2= NXz0d3pZW0GQR1XS
LCLC-97TM1 NXvqSG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjFfGVKSzVyPUOyMlE6PjRizszN NUXJVJdnW0GQR1XS
NCI-H1304 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN{LkOzNFEh|ryP NYfHPYpZW0GQR1XS
KP-N-YS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mTWM2OD1|Mj61PVc{KM7:TR?= M3uxZ3NCVkeHUh?=
NCI-H1770 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLnSZdGUUN3ME2zN{4yPjR6IN88US=> MVTTRW5ITVJ?
EM-2 NF;wfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOzPG1WUUN3ME2zN{43PTB2IN88US=> NVH0OVBUW0GQR1XS
ChaGo-K-1 M2LWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzhPFdKSzVyPUOzMlczOzZizszN M3XJbHNCVkeHUh?=
ACHN NFPoNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXmRlBKSzVyPUOzMlg{QDVizszN NXPscJZyW0GQR1XS
MN-60 NE\TboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX71Wm5HUUN3ME2zN{45PTR2IN88US=> MnzTV2FPT0WU
EW-18 NW\JUmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PNOWlEPTB;M{OuPFk4OSEQvF2= M{DMOXNCVkeHUh?=
KGN NInsbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvrfFRVUUN3ME2zOU44Ojl{IN88US=> M2GwcnNCVkeHUh?=
U031 M3fmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO2fFVNUUN3ME2zOU45OTN{IN88US=> NVHoTHZ[W0GQR1XS
HMV-II M4TlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;VSpNzUUN3ME2zOk4xPzd2IN88US=> NIPMNHdUSU6JRWK=
L-363 NWL1SIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXezcWV2UUN3ME2zO{43PDV3IN88US=> NXLuUlBpW0GQR1XS
NCI-H1155 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PhWGlEPTB;M{iuNFAyPSEQvF2= MnPWV2FPT0WU
NCI-H1793 NVLZSpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN6LkGwNlYh|ryP NETwcWtUSU6JRWK=
P30-OHK M{\v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH2R4lnUUN3ME2zPE4yOzN{IN88US=> Mn\DV2FPT0WU
AN3-CA M17Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLW[VVKSzVyPUO4MlE3OTVizszN M13LNnNCVkeHUh?=
UACC-257 M3H2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW2TWM2OD1|OD63PUDPxE1? MWDTRW5ITVJ?
MCF7 NFnCZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW3PYQ1UUN3ME2zPU45PjJ7IN88US=> M4TtbnNCVkeHUh?=
KP-N-YN M4D4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTYTWM2OD12MD60Nlg2KM7:TR?= NYToOXE2W0GQR1XS
T98G MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjzOXRKSzVyPUSwMlQ6PTdizszN M{\K[HNCVkeHUh?=
HGC-27 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHkTWM2OD12Mz6yO|Qh|ryP MY\TRW5ITVJ?
NCI-H1092 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfQfWdKSzVyPUSzMlI5QTVizszN MYLTRW5ITVJ?
KARPAS-299 NH3XellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR|LkOwO|Eh|ryP NYrwVWY6W0GQR1XS
LB1047-RCC NWHYZml{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3lPJJKSzVyPUS0Mlk6PTlizszN NGDXbW5USU6JRWK=
786-0 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Kz[GlEPTB;NEWuOlUh|ryP NIm1dFVUSU6JRWK=
HCC2157 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR4LkCzOVkh|ryP MXXTRW5ITVJ?
NY NHTYNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn3dWRKSzVyPUS2MlE4PzhizszN MnjYV2FPT0WU
EFM-19 NELFcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fjW2lEPTB;NE[uO|U{OyEQvF2= M3PqcXNCVkeHUh?=
EW-16 M1LkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTR4Lke4NFYh|ryP NUnVUYM{W0GQR1XS
UM-UC-3 M320Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR4LkiwOVkh|ryP NU\CeHFvW0GQR1XS
HT-29 M2jNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LFN2lEPTB;NEeuPFc6OiEQvF2= MV3TRW5ITVJ?
LN-405 M4flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\LSpJKSzVyPUS4MlA5OjdizszN M4jMc3NCVkeHUh?=
NCI-H727 NI\WN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5[pZWUUN3ME20PE44PzJ4IN88US=> MlP4V2FPT0WU
D-502MG M13hPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WwfWlEPTB;NEiuPVY4PiEQvF2= MYrTRW5ITVJ?
GMS-10 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXkUWZKSzVyPUS5MlI6PzRizszN NETsd3hUSU6JRWK=
MEL-JUSO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP4dGtKSzVyPUS5MlM1PyEQvF2= MUHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MEK / MEK / p-ERK / ERK / p-FAK(S910); 

PubMed: 23076151     


WM793 and WM793-Res NRAS cells were seeded overnight in the absence of PLX4720 and then treated with 1 μm PLX4720 for times ranging from 0 to 24 h. Samples were analyzed by Western blotting for phospho-MEK, total MEK, phospho-ERK1/2, total ERK1/2, phospho-S910 FAK, and total FAK.

p-EGFR 1173 / EGFR / p-Akt / Akt; 

PubMed: 26023796     


Three BRAF(V600E) glioma cell lines, NMC-G1, AM38 and DBTRG-05MG were subjected to a 24 hour time course treatment with 5 μM PLX4720 in the presence or absence of 1 μM HKI-272. These cells were serum starved for 16 hours before being stimulated with 10% FBS and harvested for immunoblotting analysis. Cells treated with PLX4720 alone showed an initial suppression of MEK and ERK phosphorylation followed by a profound rebound of MAPK pathway activation as early as one hour post-PLX4720 treatment. Elevated levels of EGFR phosphorylation were also observed in the PLX4720 treated cells. The extent of Akt phosphorylation increased upon PLX4720 treatment, although the extent varies between cell lines. In contrast, no reactivation of EGFR, MEK, ERK or Akt was observed in cells pre-treated with HKI-272.

p27 / Cyclin D1 / pRb; 

PubMed: 21828154     


Immunoblot analysis revealed that PLX4720 (3 μM) decreased levels of phosphorylated ERK, decreased levels of cyclin D1, increased levels of p27, and decreased levels of phosphorylated Rb in BRAF-mutant (OCM3) cells. On the contrary, in Gα-mutant (OMM1.3) UM cells, PLX4720 induced a paradoxical increase in phosphorylated ERK and Rb levels and an early increase in cyclin D1 levels but did not stimulate p27 levels.

pAkt(Ser473) / pAkt(Thr308); 

PubMed: 21828154     


Immunoblot analysis revealed that both AZD6244 and PLX4720 induced an early (within 2–6 hours of exposure) increase in the levels of phosphorylated Akt (at residues Ser473 and Thr308) in both BRAF-mutant OCM3 and Gα-mutant OMM1.3 cells. Eventually, and with prolonged drug exposure, the phosphorylation of Akt returned to baseline in Gα-mutant OMM1.3 cells and decreased even below baseline levels in BRAF-mutant OCM3 cells.

23076151 26023796 21828154
Immunofluorescence
LAMP1; 

PubMed: 30979895     


Representative images of LysoTracker Red (red) and LAMP1 (green) immunostaining of PLX4720 (1 μM, 12 h-treated) A375 cells with depletion of the indicated genes. Note the reduced lysosome staining in PLX4720-treated cells upon TFEB depletion. 

ZKSCAN3 / TFEB ; 

PubMed: 30979895     


Representative confocal images of subcellular translocation of endogenous TFEB (green) and ZKSCAN3 (red) in A375 cells treated with PLX4720 (1 μM, 12 h). n = 3 independent experiments. 

30979895
Growth inhibition assay
Cell viability; 

PubMed: 27848137     


AM-38 and DBTRG-05MG cells were treated for 5 days. Media was changed once every 3 days. Cell viability was measured using WST-1 assay. Error bars indicate the variation between triplicate measurements. PLX4720 and PD0325901 alone or in combination reduced cell viability significantly. However, combined therapy led to the most significant cell viability reduction compared to either monotherapy in both AM-38 and DBTRG-05MG cell lines.

27848137
ELISA
mIFN-γ; 

PubMed: 23204132     


(C, D and E) IFN-γ secretion by pmel-1 T cells co-cultured with transduced melanoma cells (after cell sorting) that had been pre-treated with the indicated concentrations of PLX4720, as determined by ELISA. (*P<0.05, ** P<0.01) Data are representative of 3 independent experiments.

23204132
In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro Raf kinase activities:

The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:[1]
- Collapse
  • Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 mM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
  • Dosages: 5, 20, or 100 mg/kg
  • Administration: Oral gavage once or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.83
Formula

C17H14ClF2N3O3S

CAS No. 918505-84-7
Storage powder
in solvent
Synonyms N/A
Smiles CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you recommend to make working solution for intraperitoneal injection into mice?

  • Answer:

    PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy PLX-4720|PLX-4720 ic50|PLX-4720 price|PLX-4720 cost|PLX-4720 solubility dmso|PLX-4720 purchase|PLX-4720 manufacturer|PLX-4720 research buy|PLX-4720 order|PLX-4720 mouse|PLX-4720 chemical structure|PLX-4720 mw|PLX-4720 molecular weight|PLX-4720 datasheet|PLX-4720 supplier|PLX-4720 in vitro|PLX-4720 cell line|PLX-4720 concentration|PLX-4720 nmr|PLX-4720 in vivo|PLX-4720 clinical trial|PLX-4720 inhibitor|PLX-4720 MAPK inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID